May 19, 2016 -MolecuLight exhibited for the very first time at the 26th annual European Wound Management Association (EWMA) Conference
MolecuLight exhibited for the very first time at the 26th Edition of the European Wound Management Association (EWMA) conference that took place in Bremen, German in May 11-13 2016. The conference was organized
… Read MoreApril 5, 2016 -
MolecuLight Inc. exhibited at the 2016 SAWC Spring Conference that took place on April 13-17 at the Georgia World Congress Center in Atlanta, GA, USA.
There were over 150 Exhibitors from around the World.
Dr. Stephan Landis MD, FRCP(C) gave an oral poster presentation on Determining
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.